Quick answer: CBD is not banned. What changed in 2026 is the federal definition of hemp. Section 781 of the fiscal 2026 appropriations law replaced the old delta-9-only 0.3 percent threshold with a total-THC standard and added a cap of 0.4 milligrams of total THC per finished container. The compliance date, originally 12 November 2026, was pushed to 11 December 2026. Non-intoxicating CBD isolate and most THC-remediated broad-spectrum products clear the new bar. Traditional full-spectrum tinctures and hemp-derived THC products generally do not.
What actually changed in federal hemp law
The 2018 Farm Bill defined hemp by a single number: no more than 0.3 percent delta-9 THC on a dry weight basis. That definition was written for farmers growing fiber and flower, not for a retail industry selling gummies, seltzers and vape carts. Because the test applied to delta-9 THC in raw plant material, a whole product category grew up around cannabinoids that were either converted in a lab or measured in ways the statute never anticipated.
Congressional Research Service summaries published in August 2026 describe the shift plainly. The new language moves federal hemp policy to a total-THC standard, which counts THCA after conversion rather than delta-9 alone, and it excludes intermediate and final hemp-derived cannabinoid products containing more than a trace quantity of THC or of other cannabinoids with similar intoxicating effects. The figure applied to finished goods is 0.4 milligrams of total THC per container.
Why the deadline moved to 11 December 2026
The original effective date was 12 November 2026. H.R. 6500 shifted it to 11 December 2026, giving Congress roughly one more month to move a dedicated hemp regulatory bill before the exclusion takes hold. A bipartisan bill filed on 22 July 2026 would preserve sales of certain hemp-derived THC products under a federal framework instead of an outright exclusion, and separate industry proposals would set per-serving rather than per-container limits.
Nothing in that process is settled. Two things are true at once: the statutory change is real and dated, and the details could still be amended before December. The USDA has separately delayed enforcement of its requirement that hemp be tested at a DEA-registered laboratory until 31 December 2026, which tells you how much of the compliance machinery is still being assembled.
Is CBD still legal?
For non-intoxicating CBD, yes, at the federal controlled-substance level. Cannabidiol itself is not the target of the new language. THC content is. This is where much of the panic in consumer forums has gone wrong: a CBD isolate capsule with no detectable THC is no more restricted in December than it was in January.
The separate question is food and supplement law, and that has not changed. The FDA has maintained since January 2023 that existing dietary supplement and food additive pathways are not appropriate for CBD, and it has asked Congress for a new regulatory route. Epidiolex, approved in 2018 for Lennox-Gastaut and Dravet syndromes and extended in 2020 to tuberous sclerosis complex, remains the only FDA-approved CBD drug. CBD products therefore sit in a gap: widely sold, not federally controlled, and not formally authorised as supplements. Our explainer on CBD, hemp and THC covers how those categories separate.
The 0.4 milligram math is tighter than it sounds
Run the numbers on a real product and the significance becomes obvious. A 30 millilitre full-spectrum tincture weighs roughly 28 to 30 grams. Even at a fraction of the old legal THC ceiling, that bottle carries several milligrams of total THC. Many compliant full-spectrum tinctures on shelves today contain somewhere between 9 and 30 milligrams of total THC per bottle. Against a 0.4 milligram per container cap, that is roughly 20 to 75 times over.
In other words, the per-container structure does not trim the top of the market. It redraws the line at effectively zero THC for finished goods. The products that survive unchanged are the ones whose certificates of analysis already read ND, or below the limit of quantitation, for THC.
Which CBD types pass the new test
- CBD isolate: a single cannabinoid with no THC. Passes comfortably.
- Broad spectrum: THC removed during remediation. Usually passes, provided the COA shows non-detect rather than a small positive number.
- Full spectrum: retains trace THC by design. Most current formulations exceed 0.4 milligrams per container and would need reformulation or smaller packaging.
- Hemp-derived delta-8, delta-9 and THCP products: squarely inside the exclusion.
How to read a COA against the 2026 rule
The habit worth building is simple: stop reading milligrams per serving and start reading milligrams per container. A lab report that lists 0.01 percent THC tells you nothing useful until you multiply it by the net weight of the bottle.
- Find total THC, not delta-9 alone. Total THC equals delta-9 THC plus 0.877 times THCA.
- Convert the percentage to milligrams using the net weight on the label, then compare with 0.4 milligrams for the whole container.
- Prefer reports stating ND or below LOQ for THC rather than a small positive figure.
- Match the batch number on the report to the batch on your bottle, and check the report date.
- Confirm the lab is ISO 17025 accredited and that contaminant panels for pesticides, solvents and heavy metals are included.
Our longer checklist on what to check before buying CBD online walks through the same document line by line, and the full spectrum versus broad spectrum versus isolate comparison explains what remediation does to a cannabinoid profile.
What the evidence actually supports
Regulatory noise tends to drown out the science, so it is worth restating what is well established and what is not. The strongest human evidence for cannabidiol comes from the epilepsy trials that supported Epidiolex, where seizure frequency fell against placebo at prescription-level doses far above what a wellness tincture provides. Beyond that indication the picture is thinner. Small randomised trials and reviews on anxiety, sleep quality and chronic pain report mixed results, with heterogeneous dosing and short follow-up periods.
On safety, the World Health Organization’s 2018 critical review concluded that CBD shows no effects indicative of abuse or dependence potential in humans, a point we cover in more depth in is CBD addictive. The more practical caution is pharmacokinetic: CBD is metabolised by cytochrome P450 enzymes and can raise or lower blood levels of other drugs handled by the same pathways, including some anticoagulants and antiepileptics. Elevated liver enzymes have been reported at high doses, usually alongside valproate.
State rules still apply, and they are not converging
Federal law sets a floor, not a ceiling. States continue to run their own hemp programmes with age limits, milligram caps per serving and per package, licensing requirements for retailers, and in several cases outright bans on intoxicating hemp products. A product that satisfies the new federal definition can still be non-compliant in a specific state, and the reverse is also true during the transition period. Anyone shipping across state lines should be tracking both layers, as our guide to state delta-8 rules in 2026 illustrates.
What to do before 11 December 2026
If you use CBD for routine wellness, the sensible steps are unglamorous. Check the COA on your current bottle for total THC per container. If it reads ND, your product is unlikely to be affected. If it shows a positive figure, expect either a reformulation or a discontinuation notice, and ask the brand directly which it will be. Avoid stockpiling on the assumption that a ban is coming for CBD itself, because that is not what the statute does.
If you sell CBD, the transition is a labelling and testing exercise as much as a legal one. Per-container reporting, remediation verification, and clear separation between non-intoxicating and intoxicating SKUs are the practical requirements. Brands that already publish batch-matched, ISO 17025 lab reports will have far less work to do than those that do not.
Frequently asked questions
Does the 2026 hemp law ban CBD?
No. It changes the federal definition of hemp and excludes finished products above 0.4 milligrams of total THC per container. CBD isolate and non-detect broad-spectrum products are not banned.
When does the new rule take effect?
11 December 2026, after H.R. 6500 moved the original 12 November 2026 date. Further legislative changes before that date remain possible.
What is total THC?
Total THC accounts for THCA converting to delta-9 THC when heated. It is calculated as delta-9 THC plus 0.877 times THCA, so a product can pass a delta-9 test and fail a total-THC test.
Will full-spectrum CBD disappear?
Not necessarily, but the format has to change. Reaching 0.4 milligrams per container means either deeper THC remediation or much smaller containers, which is closer to broad spectrum than to traditional full spectrum.
Is CBD approved by the FDA?
Only as the prescription drug Epidiolex for specific seizure disorders. The FDA has not authorised CBD as a dietary supplement or conventional food ingredient.
Does CBD show up on a drug test?
Pure CBD is not what standard panels look for, but trace THC in full-spectrum products can accumulate. We cover the detail in can CBD make you fail a drug test.
This article is general information about law and research, not medical or legal advice. Regulations are changing quickly; verify current federal and state requirements before buying or selling, and speak with a qualified clinician before using CBD alongside prescription medicines.